Fineline Cube

Follow:
14499 Articles
Hengrui Pharmaceuticals Gains NMPA Approval for Phase Ib/II Study of SHR-A1811, Adebrelimab and Famitinib in Solid Tumors
CompanyDrug

Hengrui Pharmaceuticals Gains NMPA Approval for Phase Ib/II Study of SHR-A1811, Adebrelimab and Famitinib in Solid Tumors

Qure Biotechnology Secures RMB 100 Million Series C1 Financing
CompanyDeals

Qure Biotechnology Secures RMB 100 Million Series C1 Financing

Lianhuan Pharma Gains NMPA Approval for No-Spa Generic
CompanyDrug

Lianhuan Pharma Gains NMPA Approval for No-Spa Generic

Roche's Evrysdi 5mg Tablet Gains EU Commission Approval for Spinal Muscular Atrophy
CompanyDrug

Roche’s Evrysdi 5mg Tablet Gains EU Commission Approval for Spinal Muscular Atrophy

Shanghai OPM Biosciences Plans Acqusition of PharmaLegacy Labs for RMB 1.45 Billion
CompanyDeals

Shanghai OPM Biosciences Plans Acqusition of PharmaLegacy Labs for RMB 1.45 Billion

Sunshine Guojian's SSGJ-613 Meets Phase III Endpoints in Acute Gouty Arthritis
CompanyDrug

Sunshine Guojian’s SSGJ-613 Meets Phase III Endpoints in Acute Gouty Arthritis

NHSA Strengthens Pharmaceutical Pricing and Procurement Credit Evaluation Mechanism
Policy / Regulatory

NHSA Strengthens Pharmaceutical Pricing and Procurement Credit Evaluation Mechanism

China Issues Whistleblower Incentives for Drug and Medical Device Safety Violations
Policy / Regulatory

China Issues Whistleblower Incentives for Drug and Medical Device Safety Violations

China's National Health Commission Mandates Labor Pain Management Services Expansion
Policy / Regulatory

China’s National Health Commission Mandates Labor Pain Management Services Expansion

Intragrand Pharma Licenses Lenamilast to Transpire Bio for Global Development
CompanyDeals

Intragrand Pharma Licenses Lenamilast to Transpire Bio for Global Development

Consun Pharma Partners with DP Technology to Accelerate AI-Driven Kidney Disease Drug R&D
CompanyDeals

Consun Pharma Partners with DP Technology to Accelerate AI-Driven Kidney Disease Drug R&D

Innovent Biologics' IBI363 Receives Breakthrough Therapy Designation from CDE
CompanyDrug

Innovent Biologics’ IBI363 Receives Breakthrough Therapy Designation from CDE